Navigation Links
MiMedx Announces Its Support Of New CMS Packaging Payment Policy For Skin Substitutes
Date:11/29/2013

174; are 40 to 60 percent higher than the healing rates of our competitors' products.  Our strong clinical results and cost effective approach have enabled MiMedx to quickly gain market share. We believe the new reimbursement changes will enable us to continue that progress," added Bill Taylor, President and COO.

In the new system, CMS is dividing the skin substitutes into two groups for packaging purposes: high cost skin substitutes and low cost skin substitutes. Skin substitutes with an ASP amount above the weighted average of $32 per sq. cm. are classified in the high cost group and those at or below the weighted average per sq. cm. are classified in the low cost group.  The 2014 packaged rate for the low cost skin substitutes applied to DFUs and VLUs smaller than 100 sq. cm. is $409.41, and for the high cost skin substitutes is $1371.19.  As noted above, EpiFix® continues pass-through status for 2014, and it will be reimbursed on an ASP + 6% method.  It is worth noting that if EpiFix® were bundled in 2014, it would fall into the high cost packaged rate.

Taylor continued, "The size-appropriateness of our grafts, higher healing rates and fewer required applications to achieve wound closure have already enabled us to gain market share quickly. The DFU market for products such as EpiFix® is in excess of $2 billion annually.  Knowing that the VLU prevalence rate is nearly as high as the DFU rate, only with slightly larger wounds, we estimate the combined total DFU and VLU market for our EpiFix® products to be in excess of $4 billion annually.  To achieve our revenue guidance for 2014, we only need to capture 2.5% of that total possible DFU and VLU market, and that is excluding revenue from our other product lines."  

About MiMedx
MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and b
'/>"/>

SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. MiMedx To Present At Canaccord Genuity Medical Technology And Diagnostics Forum
2. MiMedx Announces Record Third Quarter Results
3. MiMedx Reports On Meeting With FDA
4. MiMedx Responds To Misleading And Inaccurate Media Reports
5. MiMedx Plantar Fasciitis Study Published In The Foot & Ankle International Journal
6. MiMedx To Present At 33rd Annual Canaccord Genuity Growth Conference
7. Mimedx Scientific Study Is Electronically Published in The International Wound Journal
8. MiMedx Announces Record Second Quarter Results
9. BioTech Companies in the News - Alliqua, Transition Therapeutics, Organovo, MiMedx Group, Keryx Biopharmaceuticals
10. MiMedx To Exceed High End Of Second Quarter Guidance
11. MiMedx to Ring NASDAQ Stock Market Opening Bell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... York (PRWEB) December 23, 2014 According to ... Long Island Affiliate of ITRA Global, the national office market ... steady recovery. This is evidenced by the third quarter’s ... stock market. Low energy costs have held inflation down ... only negative is the housing market remaining soft. , This ...
(Date:12/24/2014)... December 24, 2014 The report expects ... 19.7% by 2019. It also provides a carefully analyzed ... and challenges for the market. , Full Copy of ... report, the global market for cell expansion will keep ... It expects this growth to be driven by rapid ...
(Date:12/24/2014)... 23, 2014 Vermillion, Inc. (Nasdaq:   ... disease, announced today that investors including Oracle Investment ... LLC and several Vermillion directors have agreed to ... Vermillion,s common stock and warrants to purchase unregistered ... placement.  Under the terms of ...
(Date:12/24/2014)... SARASOTA, Fla. , Dec. 23, 2014  Rock ... today that it has filed a Clinical Trial Application ... Medicines Healthcare products Regulatory Agency (MHRA) seeking regulatory approval ... its lead molecule, Anatabine Citrate. Contingent on ... to conduct a Phase I trial to assess the ...
Breaking Biology Technology:ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3
... one Delaware man,s vision,comes true, Americans will become ... with breast cancer, and to get started on ... an awareness campaign in his home state this,month., ... Tumor Foundation,and early this month kicked off a ...
... Agreement with U.S. Attorney,s, Office for Eastern District of ... Settles State Cases with ... Cephalon, Inc. (Nasdaq:,CEPH) announced today it has finalized a ... for the Eastern District of,Pennsylvania, the U.S. Department of ...
... Publications --, BRITISH COLUMBIA, Canada, Sept. 29 ... VENTURE: IXS;, http://www.ixsbio.com ), a drug development company ... its Dynamic Cross Linking,(DXL(TM)) technology, announces Jeff Morhet, ... company also announces the featuring of,Mr. Morhet in ...
Cached Biology Technology:Delaware Man Spearheads Brain Tumor Awareness 2Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 2Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 3Cephalon Concludes All Outstanding Federal and State Government Investigations into the Company's Sales and Promotional Practices 4InNexus Biotechnology CEO to Present at BioContactQuebec 2008 2
(Date:12/22/2014)...  The 2014 Holiday Season may be the ... Market Intelligence reports that the long anticipated floodgates ... forecasts that intensifying demand for smart phones, tablets, ... drive a global market of 2.5 billion users ... According to Maxine Most ...
(Date:12/19/2014)... LAS VEGAS , Dec. 18, 2014   ... platform built for the post-password and Internet of Things ... additional seed funding. The venture round was led by ... Pantera Capital, Rimrock Venture Partners, VegasTechFund, and others.  LaunchKey ... the new funding to expand its team and bring ...
(Date:12/17/2014)... Dec. 16, 2014 Valencell, a leader in ... biometric technology to industry leaders such as Intel, Jabra, ... validated, biometric wearable products. These products will be showcased ... Las Vegas . "Our ... flexible and robust – with the clinical data to ...
Breaking Biology News(10 mins):First Season of Holiday Shopping with Mobile Biometric Payments Wraps Up With a Present for Biometrics Industry: A Rosy Forecast for More Than 2 Billion Users of 4.8 Billion Mobile Biometric Devices by 2020 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2
... Illinois at Chicago College of Pharmacy are attempting ... antipsychotic medication works in adults and children and ... a popular "atypical" antipsychotic medication, is used to ... disorder. , Jeffrey Bishop, assistant professor of ...
... With wheat stem sawfly natural enemies in demand, ... increasing their availability. , This fall, the ... mass-rearing parasitic wasps that attack wheat stem sawfly ... plants. The team includes entomologists David Weaver, master's ...
... tool developed at Cambridge University represents a breakthrough in ... Huntington's disease. , Researchers have developed an effective ... the disease, using an automated touch screen. It is ... more effectively the cognitive difficulties in other neurodegenerative disorders ...
Cached Biology News:Studies look at how genes affect antipsychotic drug response 2Rearing an army to save wheat 2Rearing an army to save wheat 3New technology to speed up research into Huntington's disease 2New technology to speed up research into Huntington's disease 3
Kanamycin is used for selection of resistant bacteria. C18H36N4O11xH2SO4. Contains 10 mg/ml kanamycin (base) utilizing kanamycin sulfate in 0.85% saline....
Request Info...
...
... Agarose-HR High Resolution - ... from 50 to 1000 ... for sizing PCR fragments, ... by restriction enzyme digestion, ...
Biology Products: